As of May 12, 2018, according to the EP Registry, it is still under examination. The US version of this application was granted on February 4th, 2014 as US864661B2.
What is covered is defined by the claims. Here is the first claim of the US patent:
A combination comprising:
(i) a therapeutically effective amount of a beta-3 adrenergic receptor agonist selected from the group
consisting of solabegron and pharmaceutically acceptable salts
(ii) a therapeutically effective amount, or a
sub-therapeutically effective amount, of a muscarinic receptor
antagonist selected from the group consisting of tolterodine,
oxybutynin, trospium, solifenacin, darifenacin, propiverine,
fesoterodine, and pharmaceutically acceptable salts thereof,
combination being useful for relieving one or more symptoms of
overactive bladder in a synergistic manner, versus the individual
components (i) and (ii), wherein said one or more symptoms of
overactive bladder are selected from the group consisting of frequency
of urgency, nocturia, increase in urinary micturition frequency, and
As you can see, the muscarinic receptor antagonist is specified from a group of seven compounds and salts thereof.
The claims in the US version may not be the same as other versions of this patent so if they get granted you will need to review those separately to see what is covered.